Riik: Singapur
keel: inglise
Allikas: HSA (Health Sciences Authority)
Bimatoprost; Timolol maleate 6.8mg/ml eqv. to Timolol base
ABBVIE PTE. LTD.
S01ED51
0.3mg/ml
SOLUTION, STERILE
Bimatoprost 0.3mg/ml; Timolol maleate 6.8mg/ml eqv. to Timolol base 5mg/ml
OPHTHALMIC
Prescription Only
Allergan Pharmaceuticals Ireland
ACTIVE
2008-12-29
GANFORT™ eye drops, solution Bimatoprost 0.3 mg/mL and timolol 5.0 mg/mL DESCRIPTION Each mL contains: 0.3 mg bimatoprost and 5 mg timolol equivalent to 6.8 mg of timolol maleate, benzalkonium chloride as preservative, sodium chloride, dibasic sodium phosphate heptahydrate, citric acid monohydrate, hydrochloric acid or sodium hydroxide (to adjust pH), purified water. CLINICAL PHARMACOLOGY PHARMACODYNAMIC PROPERTIES _Pharmacotherapeutic group: _ Ophthalmological – beta-blocking agents – timolol, combinations_ _ ATC code: SO1ED 51 _Mechanism of action: _ GANFORT™ consists of two active substances: bimatoprost and timolol maleate. These two components decrease elevated intraocular pressure (IOP) by complementary mechanisms of action and the combined effect results in additional IOP reduction compared to either compound administered alone. GANFORT™ has a rapid onset of action. Bimatoprost is a potent ocular hypotensive agent, which selectively mimics the effects of naturally occuring prostamide F 2α . It is structurally related to prostaglandin F 2α (PGF 2α ), except that it is electrochemically neutral by virtue of the ethanolamide group at position C1. It is pharmacologically unique and acts through an identified prostamide receptor. The prostamide receptor has been structurally identified as a heterodimer of an alternative mRNA splicing variant of the prostanoid FP receptor (alt.FP4 ) and the FP wild type. The efficacy of bimatoprost may be related to a dual mechanism of action on aqueous humour outflow that involves both the uveoscleral and the trabecular meshwork/Schlemm’s canal pathways. Studies in living human subjects, human eyes in organ culture, and studies on human ciliary smooth muscle cells, trabecular meshwork cells, and endothelial cells of Schlemm's canal all indicate that bimatoprost stimulates both trab Lugege kogu dokumenti
GANFORT® eye drops, solution Bimatoprost 0.3 mg/mL and timolol 5.0 mg/mL DESCRIPTION Each mL contains: 0.3 mg bimatoprost and 5 mg timolol equivalent to 6.8 mg of timolol maleate, benzalkonium chloride as preservative, sodium chloride, dibasic sodium phosphate heptahydrate, citric acid monohydrate, hydrochloric acid or sodium hydroxide (to adjust pH), purified water. CLINICAL PHARMACOLOGY PHARMACODYNAMIC PROPERTIES _Pharmacotherapeutic group:_ Ophthalmological – beta-blocking agents – timolol, combinations ATC code: SO1ED 51 _Mechanism of action:_ GANFORT® consists of two active substances: bimatoprost and timolol maleate. These two components decrease elevated intraocular pressure (IOP) by complementary mechanisms of action and the combined effect results in additional IOP reduction compared to either compound administered alone. GANFORT® has a rapid onset of action. Bimatoprost is a potent ocular hypotensive agent, which selectively mimics the effects of naturally occuring prostamide F 2α . It is structurally related to prostaglandin F 2α (PGF 2α ), except that it is electrochemically neutral by virtue of the ethanolamide group at position C1. It is pharmacologically unique and acts through an identified prostamide receptor. The prostamide receptor has been structurally identified as a heterodimer of an alternative mRNA splicing variant of the prostanoid FP receptor (alt.FP4 ) and the FP wild type. The efficacy of bimatoprost may be related to a dual mechanism of action on aqueous humour outflow that involves both the uveoscleral and the trabecular meshwork/Schlemm’s canal pathways. Studies in living human subjects, human eyes in organ culture, and studies on human ciliary smooth muscle cells, trabecular meshwork cells, and endothelial cells of Schlemm's canal all indicate that bimatoprost stimulates both trabecular and uveoscleral outflow pathways. Timolol is a beta 1 and beta 2 non-selective adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocard Lugege kogu dokumenti